Abiomed has announced a rise in shares due to a less-than-expected CMS cut to reimbursements for the company’s heart pump, Impella. The Centers for Medicaid and Medicare Services initially proposed a 35% cut to reimbursement, but only 19% was actually implemented. Last week the company reported positive earnings results in the previous quarter and the company is positive that this share increase will only better the Impella heart pump’s future. Read the full article here.